サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784138

低分子CDMOの世界市場

Small Molecule CDMO

出版日
ページ情報
英文 225 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
低分子CDMOの世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 225 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

低分子CDMOの世界市場は2030年までに米国で1,102億米ドルに達する見込み

2024年に786億米ドルと推定される低分子CDMOの世界市場は、2024年から2030年にかけてCAGR 5.8%で成長し、2030年には1,102億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである医薬品原薬は、CAGR 4.7%を記録し、分析期間終了時には698億米ドルに達すると予想されます。医薬品完成品セグメントの成長率は、分析期間中CAGR 7.9%と推定されます。

米国市場は206億米ドルと推定、中国はCAGR 5.8％で成長予測

米国の低分子CDMO市場は2024年に206億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに178億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.3％と5.0％と予測されています。欧州では、ドイツがCAGR 4.8%で成長すると予測されています。

世界の低分子CDMO市場- 主要動向と促進要因のまとめ

なぜ低分子CDMOが注目を集めているのか？医薬品開発・製造におけるCDMOの役割を検証する

医薬品開発の複雑化と専門化した開発・製造受託機関（CDMO）に対する需要の高まりにより、低分子CDMOは製薬業界における重要なプレーヤーとして位置づけられています。従来の医薬品製剤の骨格を形成する低分子は、その幅広い治療用途、費用対効果、確立された規制経路により、医薬品市場を独占し続けています。製薬企業が製造・開発プロセスを専門のCDMOにアウトソーシングする方向にシフトしているため、市場は大きく拡大しています。迅速な医薬品開発、コストの最適化、柔軟な製造能力に対する需要の高まりが、低分子CDMOの必要性をさらに高めています。大企業から新興バイオテクノロジー企業に至るまで、バイオ医薬品企業は、規制遵守と製造の拡張性を確保しながら市場投入までの時間を短縮するために、こうしたCDMOに依存しています。製薬業界の状況が進化するにつれ、低分子CDMOは創薬と商業生産のギャップを埋める役割をさらに果たすことが期待されています。

技術の進歩はどのように低分子CDMOのイノベーションを促進しているのか？原薬製造とプロセス最適化の進歩を探る

合成化学、プロセスの最適化、自動化における技術革新は、低分子CDMOの効率を大幅に向上させています。連続製造技術はゲームチェンジャーとして登場し、リアルタイムのモニタリング、歩留まり効率の向上、廃棄物の削減を可能にしました。ハイスループット・スクリーニングやAIによる医薬品合成モデリングを含む高度な分析技術は、化合物の選択とプロセス開発を合理化しました。さらに、グリーンケミストリーの原則が統合されたことで、環境に優しい溶媒や酵素触媒技術が採用され、環境への影響を最小限に抑え、世界の持続可能性の目標に沿ったものとなっています。モジュール式生産設備とシングルユース・バイオリアクターの使用により、オペレーションの柔軟性がさらに向上し、CDMOは変化する市場の需要に迅速に対応できるようになりました。研究開発とデジタル化への投資が増加する中、低分子CDMOは革新、自動化、スケーラブルな製造ソリューションを通じて医薬品開発パイプラインを強化する態勢を整えています。

低分子CDMO市場の成長を妨げる課題とは？規制、サプライチェーン、コスト圧力への対応

低分子CDMOの需要が高まっているにもかかわらず、厳しい規制遵守、サプライチェーンの制約、コスト圧力など、いくつかの課題が残っています。製薬業界は規制が厳しく、米国FDAや欧州医薬品庁（EMA）などのガイドラインが進化しているため、新たな品質・安全基準への継続的な適応が求められています。世界の規制承認の複雑さは医薬品開発スケジュールを遅延させ、CDMOとその顧客双方のコスト負担を増大させます。世界の危機や原料不足によって深刻化したサプライチェーンの混乱は、原薬（API）の調達や生産能力に影響を及ぼしています。加えて、CDMO間の激しい競争は価格圧力につながり、主要企業は高品質のサービスを提供しながら業務効率を維持することが求められています。このような課題に対処するためには、規制遵守の枠組み、多様なサプライチェーン、費用対効果の高い生産手法への戦略的投資が必要であり、調査手法の持続的成長が求められています。

低分子CDMO市場の成長を促すものは何か？主な拡大要因と業界動向の特定

低分子CDMO市場の成長は、医薬品製造のアウトソーシング需要の増加、合成化学の進歩、特殊治療薬の台頭など、いくつかの要因によってもたらされています。受託ベースの医薬品開発が好まれるようになったことで、製薬会社は専門のCDMOと提携するようになり、社内のインフラの必要性が減り、医薬品の商業化が加速しています。精密医療と標的低分子治療の拡大により、ニッチな医薬品開発に特化したCDMOのビジネスチャンスがさらに広がっています。さらに、新興市場の台頭とアジア太平洋やラテンアメリカにおける医薬品投資の増加は、世界展開を目指すCDMOに新たな成長の道を開いています。製薬業界が技術の進歩や規制の変更によって進化を続ける中、低分子CDMOは今後も医薬品開発の要であり続け、世界中で技術革新と大規模生産を支えていくと予想されます。

セグメント

製品（医薬品有効成分、最終医薬品）、タイプ（先発医薬品、ジェネリック医薬品）、用途（がん、心血管疾患、中枢神経系疾患、自己免疫／炎症、その他）

調査対象企業の例

  • Aenova Group
  • AGC Biologics
  • Alcami Corporation
  • Apeloa Pharmaceutical
  • Aurigene Pharmaceutical Services
  • Boehringer Ingelheim
  • Cambrex Corporation
  • Catalent, Inc.
  • CordenPharma International
  • CoreRx, Inc.
  • Delpharm
  • Emergent BioSolutions
  • Eurofins Scientific
  • Fujifilm Diosynth Biotechnologies
  • Hovione
  • Labcorp Drug Development
  • Lonza Group
  • MilliporeSigma
  • Patheon（Thermo Fisher Scientific）
  • PCI Pharma Services
  • Piramal Pharma Solutions
  • Recipharm AB
  • Samsung Biologics
  • Siegfried Holding AG
  • Teva Pharmaceutical Industries
  • Thermo Fisher Scientific
  • Veranova
  • Wheeler Bio
  • WuXi AppTec
  • Zhejiang Huahai Pharmaceutical

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32963

Global Small Molecule CDMO Market to Reach US$110.2 Billion by 2030

The global market for Small Molecule CDMO estimated at US$78.6 Billion in the year 2024, is expected to reach US$110.2 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Active Pharmaceutical Ingredients, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$69.8 Billion by the end of the analysis period. Growth in the Finished Drug Products segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.6 Billion While China is Forecast to Grow at 5.8% CAGR

The Small Molecule CDMO market in the U.S. is estimated at US$20.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$17.8 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Small Molecule CDMO Market - Key Trends & Drivers Summarized

Why Are Small Molecule CDMOs Gaining Traction? Examining Their Role in Pharmaceutical Drug Development and Manufacturing

The increasing complexity of drug development and the rising demand for specialized contract development and manufacturing organizations (CDMOs) have positioned small molecule CDMOs as vital players in the pharmaceutical industry. Small molecules, which form the backbone of traditional drug formulations, continue to dominate the pharmaceutical market due to their broad therapeutic applications, cost-effectiveness, and well-established regulatory pathways. With pharmaceutical companies shifting focus toward outsourcing manufacturing and development processes to specialized CDMOs, the market has seen significant expansion. The rising demand for rapid drug development, cost optimization, and flexible manufacturing capabilities has further fueled the need for small molecule CDMOs. Biopharmaceutical companies, ranging from large-scale enterprises to emerging biotech firms, rely on these CDMOs to accelerate time-to-market while ensuring regulatory compliance and production scalability. As the pharmaceutical landscape evolves, small molecule CDMOs are expected to play an even greater role in bridging the gap between drug discovery and commercial production.

How Are Technological Advancements Driving Innovation in Small Molecule CDMOs? Exploring Advancements in API Manufacturing and Process Optimization

Technological innovations in synthetic chemistry, process optimization, and automation have significantly enhanced the efficiency of small molecule CDMOs. Continuous manufacturing technologies have emerged as a game-changer, allowing for real-time monitoring, improved yield efficiency, and reduced waste. Advanced analytical techniques, including high-throughput screening and AI-driven drug synthesis modeling, have streamlined compound selection and process development. Additionally, the integration of green chemistry principles has led to the adoption of eco-friendly solvents and enzymatic catalysis techniques, minimizing environmental impact and aligning with global sustainability goals. The use of modular production facilities and single-use bioreactors has further improved operational flexibility, enabling CDMOs to quickly adapt to changing market demands. With increasing investments in R&D and digitalization, small molecule CDMOs are poised to enhance drug development pipelines through innovation, automation, and scalable manufacturing solutions.

What Challenges Are Hindering the Growth of the Small Molecule CDMO Market? Addressing Regulatory, Supply Chain, and Cost Pressures

Despite the growing demand for small molecule CDMOs, several challenges persist, including stringent regulatory compliance, supply chain constraints, and cost pressures. The pharmaceutical industry is heavily regulated, with evolving guidelines from agencies such as the U.S. FDA and EMA requiring continuous adaptation to new quality and safety standards. The complexity of global regulatory approvals can delay drug development timelines, adding to the cost burden for both CDMOs and their clients. Supply chain disruptions, exacerbated by global crises and raw material shortages, have impacted active pharmaceutical ingredient (API) sourcing and production capabilities. Additionally, intense competition among CDMOs has led to price pressures, requiring companies to maintain operational efficiency while delivering high-quality services. Addressing these challenges requires strategic investments in regulatory compliance frameworks, diversified supply chains, and cost-effective production methodologies to ensure sustainable growth in the small molecule CDMO sector.

What’s Driving the Growth of the Small Molecule CDMO Market? Identifying Key Expansion Factors and Industry Trends

The growth in the small molecule CDMO market is driven by several factors, including increasing demand for outsourced pharmaceutical manufacturing, advancements in synthetic chemistry, and the rise of specialty therapeutics. The growing preference for contract-based drug development has encouraged pharmaceutical firms to partner with specialized CDMOs, reducing the need for in-house infrastructure and accelerating drug commercialization. The expansion of precision medicine and targeted small-molecule therapies has further created opportunities for CDMOs specializing in niche drug development. Additionally, the rise of emerging markets and increased pharmaceutical investments in Asia-Pacific and Latin America have opened new growth avenues for CDMOs seeking global expansion. As the pharmaceutical industry continues to evolve with technological advancements and regulatory changes, small molecule CDMOs are expected to remain a cornerstone of drug development, supporting innovation and large-scale production worldwide.

SCOPE OF STUDY:

The report analyzes the Small Molecule CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Active Pharmaceutical Ingredients, Finished Drug Products); Drug Type (Innovators, Generics); Application (Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Aenova Group
  • AGC Biologics
  • Alcami Corporation
  • Apeloa Pharmaceutical
  • Aurigene Pharmaceutical Services
  • Boehringer Ingelheim
  • Cambrex Corporation
  • Catalent, Inc.
  • CordenPharma International
  • CoreRx, Inc.
  • Delpharm
  • Emergent BioSolutions
  • Eurofins Scientific
  • Fujifilm Diosynth Biotechnologies
  • Hovione
  • Labcorp Drug Development
  • Lonza Group
  • MilliporeSigma
  • Patheon (Thermo Fisher Scientific)
  • PCI Pharma Services
  • Piramal Pharma Solutions
  • Recipharm AB
  • Samsung Biologics
  • Siegfried Holding AG
  • Teva Pharmaceutical Industries
  • Thermo Fisher Scientific
  • Veranova
  • Wheeler Bio
  • WuXi AppTec
  • Zhejiang Huahai Pharmaceutical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Small Molecule CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Outsourcing by Pharma and Biotech Innovators Throws the Spotlight on Small Molecule CDMO Partnerships
    • Growth in Complex Chemistry and High-Potency API Development Drives Specialized CDMO Capabilities
    • OEM Expansion Into Early-Stage and End-to-End CDMO Models Strengthens Client Lifecycle Integration
    • Surging Pipeline of Orphan Drugs, Oncology Therapeutics, and CNS Agents Spurs API Volume Growth
    • OEM Emphasis on Continuous Manufacturing, Microreactors, and Flow Chemistry Enhances Process Efficiency
    • Increasing Demand for Regulatory Compliant Facilities Drives Investment in GMP Infrastructure Expansion
    • OEM Investment in HPAPI and Controlled Substance Manufacturing Strengthens Differentiation
    • Growth in Accelerated Approval Pathways and 505(b)(2) Strategies Spurs Flexible Manufacturing Needs
    • OEM Collaboration With Innovators for Route Scouting and Synthetic Optimization Enhances Drug Viability
    • Rising Complexity of Multi-Step Synthesis and Chiral Catalysis Drives Strategic CDMO Engagement
    • OEM Focus on Real-Time Analytics, PAT Integration, and QbD Enhances Quality Assurance
    • Expansion of Bioavailability Enhancement Technologies Supports Value-Added CDMO Services
    • OEM Acquisition of CRO Capabilities Enables Seamless Transition From Preclinical to Commercial Scale
    • Increasing Regulatory Oversight in Emerging Markets Spurs Demand for US/EU Inspected CDMO Facilities
    • OEM Strategies for Geographical Diversification Mitigate Supply Chain and Geopolitical Disruptions
    • Growth in Demand for Specialized Dosage Forms Such as ODT, SR, and Nanoformulations Spurs Innovation
    • OEM Development of High-Capacity Spray Drying and Crystallization Facilities Enhances Solubility Projects
    • Rising Focus on Cost-Effective Late-Phase Scale-Up Solutions Drives Competitive Differentiation
    • OEM Integration of Digital Supply Chain, Forecasting Tools, and Batch Traceability Enhances Partner Collaboration
    • Focus on Environmental Compliance, Solvent Recovery, and Waste Reduction Reinforces ESG Credentials of CDMOs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Small Molecule CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Small Molecule CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Small Molecule CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Small Molecule CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Active Pharmaceutical Ingredients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Active Pharmaceutical Ingredients by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Finished Drug Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Finished Drug Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Finished Drug Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Innovators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Innovators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Innovators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Central Nervous System Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Central Nervous System Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Central Nervous System Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Autoimmune / Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Autoimmune / Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Autoimmune / Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • JAPAN
    • Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • CHINA
    • Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • EUROPE
    • Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Small Molecule CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Small Molecule CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • FRANCE
    • Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • GERMANY
    • Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030

IV. COMPETITION